⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 2, 2024Open Access

Figure S1 from A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin

Anirban Chakraborty Masanori Onda T. O’Shea Junxia Wei Xiufen Liu Tapan K. Bera Ira Pastan

View Full Paper

Ask AI

Bookmark

Share

Abstract

Figure S1 shows BsAb 4 and BsAb 5 concentration over time in each mouse for half-life determination.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chakraborty et al. (2024) studied this question.

synapsesocial.com/papers/68e61b6eb6db6435875adb48 https://doi.org/10.1158/1535-7163.26145078.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Method S1 from A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin2024
2Supplementary Method S1 from A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin2024
3Figure S2 from A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin2024
4Data from A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin2024
5Figure S3 from A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin2024